ANNE One-Wellue Device for Vital Sign Monitoring
(ANNE One TMRCT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if the ANNE One-Wellue Device Array, a wireless device, simplifies and speeds up vital sign checks for hospital patients. Researchers will compare this device to standard methods for measuring heart rate and blood pressure. The study includes patients admitted to a specific unit at Northwestern Memorial Hospital who can speak English and are not in isolation. As an unphased trial, it offers patients the chance to contribute to innovative research that could enhance hospital care.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that the ANNE One-Wellue Device is safe for vital sign monitoring?
Research has shown that the ANNE One-Wellue Device Array is safe for monitoring vital signs. The FDA has cleared the device, confirming it meets safety standards for medical use. Suitable for newborns, children, and adults, it is safe for all ages.
Wearable sensors in the device continuously track vital signs, reducing the need for frequent manual checks, which can be more disruptive. Although new in some areas, its use in continuous monitoring has shown promise, with few issues reported.
In summary, health authorities have approved the ANNE One-Wellue Device Array, confirming its safety and tolerance for users.12345Why are researchers excited about this trial?
Researchers are excited about the ANNE One-Wellue Device because it offers a new way to monitor vital signs continuously and non-invasively. Unlike traditional methods that require periodic checks and manual input, this device array allows for real-time monitoring, potentially leading to quicker responses to changes in a patient's condition. This could improve patient care by reducing the time between vital sign changes and medical intervention.
What evidence suggests that the ANNE One-Wellue Device is effective for vital sign monitoring?
Research shows that the ANNE One-Wellue Device Array, which participants in this trial may use, speeds up the process of checking vital signs, such as heart rate and blood pressure. One study found that continuous monitoring with this device reduced the need for intensive care and lowered death rates. The device uses Bluetooth to send health data wirelessly, enabling healthcare providers to access vital sign information more quickly. Other research supports that remote monitoring systems effectively track health signs, allowing for quick responses to changes. Overall, early findings suggest that this technology can improve patient care by simplifying the collection of vital signs.16789
Who Is on the Research Team?
Gregory (Randy) R Smith Jr, MD MS
Principal Investigator
Northwestern University Feinberg School of Medicine
Are You a Good Fit for This Trial?
This trial is for healthcare staff on a general medical floor who regularly measure and chart patients' vital signs. It's designed to see if using a wireless Bluetooth device array changes the time they spend on these tasks.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are monitored for time spent obtaining and charting vital signs using either routine methods or the ANNE One device array
Follow-up
Participants' sleep quality and satisfaction are assessed post-discharge
What Are the Treatments Tested in This Trial?
Interventions
- ANNE One-Wellue Device Array
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northwestern University
Lead Sponsor
University of Minnesota Medical School/University of Minnesota Foundation
Collaborator
Sibel Health Inc.
Industry Sponsor